Extended indication xtension of indication to include treatment of adult patients with previously untreated CD30+ advanc
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Brentuximab vedotin
Domain Hematology
Reason of inclusion Indication extension
Main indication Hodgkin's lymphoma
Extended indication xtension of indication to include treatment of adult patients with previously untreated CD30+ advanced (including Stage III) Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine and dacarbazine (AVD).
Proprietary name Adcetris
Manufacturer Takeda
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date March 2023
Expected Registration January 2024
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.